ACR25 Best Abstracts - Day 3

Save

Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.

Are we putting the CAR-T before the horse?

Save

CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.

The Rapidly Evolving Landscape of Cellular and Immune-based Therapies

Save

A transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we treat autoimmune diseases.

CAR-T Cell Therapies Show Promise for Autoimmune Disease at ACR Convergence 2025

Save

Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases.

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm